Key facts
- It has raised $39.0M across 2 recorded rounds; the latest was Early Stage VC ($20.3M) in Jan 2024.
- Notable investors include First Trust Capital Partners, HITLAB Innovators, Healthcare Growth Partners, Heritage Group (US).
- Conversio Health has filed 4 Form Ds with the SEC since 2020, most recently Nov 2024 ($15.8M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Conversio Health
Funding rounds
2 roundsAbout Conversio Health
Provider of pharmacotherapy management services intended to identify and overcome the challenges to optimal outcomes. The company's respiratory and chronic care management services are generally pharmacy-based models, which provide services that include targeted medical therapies as well as supplies and home delivery services, enabling patients with complex chronic respiratory conditions to get treated with unique medical drugs as per requirement.
- Sector
- Healthcare
- HQ
- San Luis Obispo, CA, United States
- Founded
- 2012
- Employees
- 53
- Website
- conversiohealth.com/
- Ownership
- Privately Held (backing)
Conversio Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Conversio Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Conversio Health in its N-PORT filings yet. We sweep new filings monthly.